Vigil Neuroscience, Inc., a microglia-focused company, engages in the development of disease-modifying therapeutics for patients, caregivers, and families affected by rare and common neurodegenerative diseases. Its lead product candidate is VGL101, a fully human monoclonal antibody (mAb) that is designed to activate triggering receptor expressed on myeloid cells 2 (TREM2) which is in Phase I for the treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia, as well as for the treatment of cerebral adrenoleukodystrophy and alzheimer's disease. The company also develops a small molecule TREM2 agonist suitable for oral delivery to treat common neurodegenerative diseases associated with microglial dysfunction. Vigil Neuroscience, Inc. was incorporated in 2020 and is headquartered in Cambridge, Massachusetts.
Earnings for Vigil Neuroscience, Inc. (VIGL)
Earnings in 2023 (TTM): $-82,638,000
According to Vigil Neuroscience, Inc.'s latest financial reports the company's current earnings (TTM) are $-82,638,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Vigil Neuroscience, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-82,638,000 | $-82,638,000 |
| 2022 | $-68,305,000 | $-67,726,000 |
| 2021 | $-43,283,000 | $-43,252,000 |
| 2020 | $-28,546,000 | $-28,546,000 |